100% / Available: immediately
Artificial intelligence is rapidly transforming molecular design and drug discovery. However, the identification of successful drug candidates requires more than generating molecules with high predicted affinity: selectivity, physicochemical properties, potential adverse effects, synthetic accessibility, and experimental feedback must be considered simultaneously.
Our research in the Computational Pharmacy group at the University of Basel focuses on developing next-generation AI approaches for drug design by combining state-of-the-art machine learning with physicochemical knowledge and molecular modeling. Representative publications from our group include:
https://doi.org/10.1038/s41467-025-63947-5
https://doi.org/10.1021/acs.jcim.2c01436
https://doi.org/10.1021/acs.jcim.1c01438
https://doi.org/10.1038/s42004-020-0261-x